^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Regimen: (oxaliplatin + capecitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/23/2020
    Excerpt:
    Gastroesophageal Junction Adenocarcinoma: Principles of systemic therapy...Preferred regimens…HER2 overexpression negative…Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin